Summary
Global Markets Direct’s, ‘Genmab A/S - Product Pipeline Review - 2016’, provides an overview of the Genmab A/S’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Genmab A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Genmab A/S
- The report provides overview of Genmab A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Genmab A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Genmab A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Genmab A/S’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Genmab A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Genmab A/S’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Genmab A/S Snapshot 5
Genmab A/S Overview 5
Key Information 5
Key Facts 5
Genmab A/S - Research and Development Overview 6
Key Therapeutic Areas 6
Genmab A/S - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Genmab A/S - Pipeline Products Glance 15
Genmab A/S - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Genmab A/S - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Genmab A/S - Drug Profiles 18
teprotumumab 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
tisotumab vedotin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
HuMax-AXL-ADC 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
IDD-004 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody 1 for Central Nervous System Disorders 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody 2 for Central Nervous System Disorders 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody 3 for Central Nervous System Disorders 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Mononclonal Antibody 1 for Oncology 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Mononclonal Antibody 2 for Oncology 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Mononclonal Antibody Conjugate for Oncology 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Genmab A/S - Pipeline Analysis 31
Genmab A/S - Pipeline Products by Target 31
Genmab A/S - Pipeline Products by Route of Administration 32
Genmab A/S - Pipeline Products by Molecule Type 33
Genmab A/S - Pipeline Products by Mechanism of Action 34
Genmab A/S - Recent Pipeline Updates 35
Genmab A/S - Dormant Projects 37
Genmab A/S - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
HuMax-CD74-ADC 38
teprotumumab 38
Genmab A/S - Company Statement 39
Genmab A/S - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43
List of Tables
Genmab A/S, Key Information 5
Genmab A/S, Key Facts 5
Genmab A/S - Pipeline by Indication, 2016 7
Genmab A/S - Pipeline by Stage of Development, 2016 9
Genmab A/S - Monotherapy Products in Pipeline, 2016 10
Genmab A/S - Partnered Products in Pipeline, 2016 11
Genmab A/S - Partnered Products/ Combination Treatment Modalities, 2016 12
Genmab A/S - Out-Licensed Products in Pipeline, 2016 13
Genmab A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
Genmab A/S - Phase II, 2016 15
Genmab A/S - Phase I, 2016 16
Genmab A/S - Preclinical, 2016 17
Genmab A/S - Pipeline by Target, 2016 31
Genmab A/S - Pipeline by Route of Administration, 2016 32
Genmab A/S - Pipeline by Molecule Type, 2016 33
Genmab A/S - Pipeline Products by Mechanism of Action, 2016 34
Genmab A/S - Recent Pipeline Updates, 2016 35
Genmab A/S - Dormant Developmental Projects,2016 37
Genmab A/S - Discontinued Pipeline Products, 2016 38
Genmab A/S, Subsidiaries 41
List of Figures
Genmab A/S - Pipeline by Top 10 Indication, 2016 7
Genmab A/S - Pipeline by Stage of Development, 2016 9
Genmab A/S - Monotherapy Products in Pipeline, 2016 10
Genmab A/S - Partnered Products in Pipeline, 2016 11
Genmab A/S - Out-Licensed Products in Pipeline, 2016 13
Genmab A/S - Pipeline by Target, 2016 31
Genmab A/S - Pipeline by Route of Administration, 2016 32
Genmab A/S - Pipeline by Molecule Type, 2016 33
Genmab A/S - Pipeline Products by Mechanism of Action, 2016 34
